Skip Navigation
Johns Hopkins Bloomberg School of Public HealthCAAT

Proceedings for TestSmart -- Endocrine Disruptors

WHERE ARE WE TODAY?

  • James D. Yager, Johns Hopkins University
  • Gary Timm, United States Environmental Protection Agency
  • Herman Koeter, OECD
  • Richard A. Becker, American Chemistry Council
  • Martin L. Stephens, Humane Society of the United States

REDUCTION

  • Chair: L. Earl Gray, Jr., United States Environmental Protection Agency

    Focus: What methods exist for increasing the quantity and quality of data obtained from whole animal testing? In particular, can additional endpoints be included in whole animal tests?

  • Chair: John McLachlan, Tulane and Xavier Universities

    Focus: What are the critical mechanistic similarities and differences between wildlife species of concern, mammalian models and humans? Do we have to test multiple species?

  • Chair: Pamela Reilly Contag, Xenogen Corporation

    Focus: Are there in vivo imaging techniques currently available that can be brought to bear on the issue of endocrine disruptor screening and testing? For which endpoints will these techniques be useful?

  • Topic: Mechanisms of endocrine disruption and novel methods for endocrine disruptor screening and testing

REPLACEMENT

  • Chair: Thomas Zoeller, University of Massachusetts

    Focus: Are there existing in vitro assays that can be used to screen and detect chemicals that disrupt the thyroid hormone system? Which endpoints would be amenable for developing in vitro assays for this purpose? Are any of these adaptable to high throughput screening?

  • Chair: Robert Brueggemeier, Ohio State University Health Sciences

    Focus: What endpoints other than receptor binding can be assessed using existing in vitro assays? How relevant are these in vitro assays to ED screening and testing? What is the potential for these to replace animal tests recommended by EDSTAC? Are any of these adaptable to high throughput screening?

  • Chair: Bernard Robaire, McGill University

    Focus: Which endpoints of concern are particularly amenable to these technologies? What is the best approach for determining sensitivity and specificity, and properly validating and standardizing these technologies? What is the best approach for establishing relevance of these technologies to endpoints/effects of known biological significance? To this end, what is the feasibility of collecting tissues from ongoing endocrine screening and testing programs for use in genomics and proteomic studies?


Ellen K. Silbergeld, Johns Hopkins University
Pamela Lein, Johns Hopkins University